The tyrosine kinase inhibitors (TKIs) imatinib and bosutinib target BCR-ABL1 in chronic myeloid leukemia (CML) significantly improve patient survival [12]; the tyrosine kinase inhibitor crizotinib demonstrates significant efficacy in treating ROS1-rearranged advanced non-small cell lung cancer [13]; and the tropomyosin receptor kinase (TRK) inhibitor larotrectinib exhibits significant and long-lasting antitumor activity in patients diagnosed with TRK fusion-positive tumors [14]. This evidence concerns the gene ROS1 and chronic myelogenous leukemia, BCR-ABL1 positive.